Ensign Peak Advisors
ALNY icon

Ensign Peak Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History

Ensign Peak Advisors’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14.4M Sell
47,829
-21,818
-31% -$6.58M 0.02% 378
2026
Q1 		$23M Buy
69,647
+11,715
+20% +$3.99M 0.04% 285
2025
Q4 		$23M Sell
57,932
-9,801
-14% -$4.34M 0.04% 274
2025
Q3 		$30.9M Sell
67,733
-32,476
-32% -$13.2M 0.05% 253
2025
Q2 		$32.7M Buy
100,209
+19,730
+25% +$5.46M 0.06% 240
2025
Q1 		$21.7M Buy
80,479
+4,015
+5% +$1.03M 0.04% 289
2024
Q4 		$18M Sell
76,464
-4,104
-5% -$1.08M 0.03% 337
2024
Q3 		$22.2M Buy
80,568
+7,095
+10% +$1.85M 0.04% 308
2024
Q2 		$17.9M Sell
73,473
-8,297
-10% -$1.31M 0.03% 330
2024
Q1 		$12.2M Sell
81,770
-5,827
-7% -$972K 0.02% 416
2023
Q4 		$16.8M Buy
87,597
+28,373
+48% +$4.83M 0.03% 327
2023
Q3 		$10.5M Buy
59,224
+11,904
+25% +$2.27M 0.02% 380
2023
Q2 		$8.99M Buy
47,320
+7,745
+20% +$1.54M 0.02% 444
2023
Q1 		$7.93M Buy
39,575
+2,482
+7% +$522K 0.02% 456
2022
Q4 		$8.82M Buy
37,093
+1,563
+4% +$333K 0.02% 444
2022
Q3 		$7.11M Sell
35,530
-1,335
-4% -$255K 0.02% 438
2022
Q2 		$5.38M Buy
36,865
+435
+1% +$61.7K 0.01% 515
2022
Q1 		$5.95M Sell
36,430
-4,330
-11% -$660K 0.01% 544
2021
Q4 		$6.91M Sell
40,760
-127,839
-76% -$23.8M 0.01% 570
2021
Q3 		$31.8M Sell
168,599
-4,144
-2% -$777K 0.07% 234
2021
Q2 		$29.3M Buy
172,743
+4,942
+3% +$724K 0.06% 259
2021
Q1 		$23.7M Buy
167,801
+57,463
+52% +$8.65M 0.05% 283
2020
Q4 		$14.3M Sell
110,338
-2,870
-3% -$383K 0.03% 367
2020
Q3 		$16.5M Buy
113,208
+37,241
+49% +$5.29M 0.04% 342
2020
Q2 		$11.3M Buy
75,967
+36,010
+90% +$4.85M 0.03% 397
2020
Q1 		$4.35M Buy
39,957
+35,266
+752% +$4.07M 0.01% 543
2019
Q4 		$540K Buy
+4,691
New +$468K ﹤0.01% 1496

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Ensign Peak Advisors's ALNY Position: Q2 2026 in Review

Ensign Peak Advisors reduced its Alnylam Pharmaceuticals (ALNY) stake by 31% in Q2 2026, selling an estimated $6.58M and leaving 47,829 shares worth $14.4M. The position accounts for 0.02% of the portfolio, ranked #378.

Ensign Peak Advisors first reported a position in ALNY in Q4 2019 and has held it in 27 quarters since. The position peaked at $32.7M in Q2 2025. 784 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Ensign Peak Advisors held 47,829 shares of Alnylam Pharmaceuticals worth $14.4M as of Q2 2026.
  • Ensign Peak Advisors sold 21,818 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $6.58M.
  • Alnylam Pharmaceuticals made up 0.02% of Ensign Peak Advisors's portfolio in Q2 2026, its #378 holding.
  • Ensign Peak Advisors first reported a position in Alnylam Pharmaceuticals in Q4 2019 and has held it in 27 quarters since.
  • Ensign Peak Advisors's Alnylam Pharmaceuticals position peaked at $32.7M in Q2 2025.
  • 784 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Ensign Peak Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.